Sunitinib is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.
For this indication, competent medicine agencies globally authorize below treatments:
Oral
50 - 50 mg
From 50 To 50 mg once every day for 28 day(s)
The recommended dose of sunitinib is 50 mg taken orally once daily, for 4 consecutive weeks, followed by a 2-week rest period (Schedule 4/2) to comprise a complete cycle of 6 weeks.
It may be taken with or without food.